Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

MNPR

Monopar Therapeutics Inc

Oct 29 • 04:00PM ET

16.21

Dollar change -1.62
Percentage change -9.09	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE MCRB AFMD ADAP EYPT ADVM CYCN CTMX XBIT GLYC

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.30	Insider Own	49.91%	Shs Outstand	2.98M	Perf Week	208.76%
Market Cap	57.06M	Forward P/E	-	EPS next Y	-6.82	Insider Trans	7.89%	Shs Float	1.76M	Perf Month	140.50%
Income	-7.12M	PEG	-	EPS next Q	-1.52	Inst Own	7.84%	Short Float	2.83%	Perf Quarter	363.21%
Sales	0.00M	P/S	-	EPS this Y	-86.15%	Inst Trans	-3.58%	Short Ratio	0.04	Perf Half Y	391.14%
Book/sh	1.73	P/B	9.37	EPS next Y	-20.18%	ROA	-81.33%	Short Interest	0.05M	Perf Year	604.78%
Cash/sh	2.02	P/C	8.01	EPS next 5Y	-	ROE	-102.31%	52W Range	1.37 - 38.50	Perf YTD	852.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-14.80%	ROI	-116.98%	52W High	-57.90%	Beta	1.25
Dividend TTM	-	Quick Ratio	6.59	Sales past 5Y	0.00%	Gross Margin	-	52W Low	1083.64%	ATR (14)	4.09
Dividend Ex-Date	-	Current Ratio	6.59	EPS Y/Y TTM	39.50%	Oper. Margin	0.00%	RSI (14)	59.51	Volatility	168.43% 48.41%
Employees	10	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	26.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	40.25%	Payout	-	Rel Volume	0.77	Prev Close	17.83
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Aug 09 BMO	Avg Volume	1.21M	Price	16.21
SMA20	95.36%	SMA50	197.13%	SMA200	321.32%	Trades		Volume	935,463	Change	-9.09%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-11-24	Initiated	Rodman & Renshaw	Buy	$50
Jan-28-21	Initiated	ROTH Capital	Buy	$49

Oct-28-24 09:15PM	Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock (GlobeNewswire) +5.32% -9.09%
04:00PM	Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-25-24 07:31AM	Monopar Therapeutics Secures License for Wilson Disease Treatment (TipRanks) -48.16%
Oct-24-24 07:00AM	Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate (GlobeNewswire) +605.40%
Oct-22-24 08:00AM	Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 (GlobeNewswire)
08:28AM	Loading…
Oct-16-24 08:28AM	Monopar Therapeutics Expands Portfolio with New Patent Filing (TipRanks)
Oct-15-24 08:00AM	Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers (GlobeNewswire)
Oct-08-24 08:30AM	Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial (TipRanks) +5.12%
Oct-07-24 08:00AM	Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers (GlobeNewswire) +10.20%
Sep-12-24 08:00AM	Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr (GlobeNewswire) +64.58%
Sep-04-24 08:00AM	Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-27-24 04:05PM	Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) -8.40% -5.83%
Aug-21-24 08:00AM	Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers (GlobeNewswire)
Aug-14-24 08:00AM	Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr (GlobeNewswire) -5.79%
Aug-12-24 12:24PM	Upcoming Stock Splits This Week (August 12 to August 16) Stay Invested (TipRanks) +6.56%
02:53PM	Loading…
Aug-09-24 02:53PM	MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024 (InvestorPlace) -19.64%
08:00AM	Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments (GlobeNewswire)
08:00AM	Monopar Therapeutics Announces 1-for-5 Reverse Stock Split (GlobeNewswire)
Jul-09-24 07:00AM	Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr (GlobeNewswire)
Jun-25-24 08:00AM	Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24 (GlobeNewswire)
Jun-11-24 07:30AM	Monopar and NorthStar Amend & Extend Collaboration (GlobeNewswire) +5.22%
Jun-10-24 08:00AM	Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting (GlobeNewswire)
Jun-05-24 06:15AM	Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely (InvestorPlace)
May-24-24 08:00AM	Monopar Announces CFO Succession (GlobeNewswire)
May-17-24 09:55AM	Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now (Zacks)
May-09-24 01:55PM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.19%
07:00AM	Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline (GlobeNewswire)
Apr-18-24 08:00AM	Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 08:00AM	Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings (GlobeNewswire)
Apr-10-24 08:00AM	Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients (GlobeNewswire) +8.36%
09:55AM	Loading…
Apr-04-24 09:55AM	Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-03-24 12:00PM	All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy (Zacks)
Mar-28-24 11:53AM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -7.60%
07:00AM	Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments (GlobeNewswire)
Mar-05-24 07:00AM	Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program (GlobeNewswire) +7.06%
Feb-27-24 07:00AM	Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial (GlobeNewswire) -10.37%
Feb-23-24 11:55AM	5 Best Rising Penny Stocks To Buy (Insider Monkey) +16.07%
Feb-22-24 07:00AM	Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers (GlobeNewswire) +96.49%
Feb-20-24 08:00AM	Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers (GlobeNewswire) +95.27%
Nov-09-23 08:37AM	Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs (GuruFocus.com)
07:00AM	Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Nov-01-23 07:00AM	Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting (GlobeNewswire) +27.91%
Oct-10-23 07:00AM	Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference (GlobeNewswire) -5.96%
Sep-05-23 07:00AM	Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 07:00AM	Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Aug-08-23 07:00AM	Monopar Provides Encouraging Camsirubicin Clinical Data Update (GlobeNewswire) +15.22%
Jul-11-23 07:00AM	Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore (GlobeNewswire)
Jun-21-23 07:00AM	Monopar to Participate in the Radiopharma Forum by the Lake 2023 (GlobeNewswire)
Jun-14-23 07:00AM	Monopar to Participate in the Maxim Groups Healthcare Virtual Conference (GlobeNewswire)
Jun-01-23 07:00AM	Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update (GlobeNewswire) +7.36%
May-29-23 09:55AM	Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-11-23 07:00AM	Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments (GlobeNewswire) -6.58%
Apr-19-23 09:55AM	Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-28-23 01:40PM	Monopar Therapeutics Shelves Development Of Validive For Radiation Therapy-Related Complication (Benzinga) -51.34%
07:00AM	Monopar to Present at the Jefferies Radiopharma Innovation Summit (GlobeNewswire)
Mar-27-23 05:00PM	Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis (GlobeNewswire)
Mar-23-23 07:00AM	Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments (GlobeNewswire)
Mar-07-23 07:00AM	Monopar to Present at the 35th Annual Roth Conference (GlobeNewswire)
Feb-27-23 07:00AM	Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials (GlobeNewswire)
Feb-14-23 12:46PM	What's Going On With Monopar Therapeutics Shares Today? (Benzinga)
07:00AM	Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin (GlobeNewswire)
Feb-05-23 08:38AM	We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate (Simply Wall St.)
Jan-26-23 07:00AM	Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT (GlobeNewswire)
Jan-18-23 07:00AM	Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2 (GlobeNewswire)
Dec-12-22 07:00AM	Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration (GlobeNewswire) -18.97%
Nov-18-22 01:10PM	Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data (Zacks) -6.42%
09:55AM	Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-16-22 10:09AM	Monopar Therapeutics Highlights Encouraging Data From Early-Stage Soft Tissue Cancer Study (Benzinga)
07:00AM	Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial (GlobeNewswire)
Nov-10-22 08:00AM	Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments (GlobeNewswire) -24.83%
Oct-27-22 08:00AM	Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 (GlobeNewswire)
Oct-19-22 08:00AM	Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting (GlobeNewswire)
Oct-12-22 08:00AM	Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting (GlobeNewswire)
Oct-05-22 08:50AM	Monopar's stock gains 13% after completing enrollment for an experimental therapy for cancer patients (MarketWatch)
08:00AM	Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis (GlobeNewswire)
Sep-28-22 08:00AM	Monopar to Present at Roth Inaugural Healthcare Opportunities Conference (GlobeNewswire)
Aug-28-22 10:49AM	Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation (Simply Wall St.)
Aug-18-22 09:55AM	Monopar Therapeutics Inc. (MNPR) Could Find Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-11-22 08:05AM	Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments (GlobeNewswire)
May-12-22 08:00AM	Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments (GlobeNewswire) -7.96%
Mar-24-22 08:00AM	Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments (GlobeNewswire)
Mar-21-22 03:18PM	Companies Like Monopar Therapeutics (NASDAQ:MNPR) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-08-22 08:00AM	Monopar to Present at the 34th Annual Roth Conference and Maxims 2022 Virtual Growth Conference (GlobeNewswire) -5.98%
Feb-15-22 08:05AM	Monopar Announces Clinical and Preclinical Program Updates (GlobeNewswire) +6.16%
Jan-07-22 07:05AM	Monopar to Present at the H.C. Wainwright BioConnect Conference (GlobeNewswire) +6.67%
Dec-08-21 08:00AM	Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial (GlobeNewswire)
Nov-12-21 08:00AM	Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments (GlobeNewswire)
Oct-27-21 08:05AM	Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma (GlobeNewswire) +8.34%
Sep-22-21 08:30AM	Companies Like Monopar Therapeutics (NASDAQ:MNPR) Are In A Position To Invest In Growth (Simply Wall St.)
Sep-16-21 08:00AM	Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma (GlobeNewswire)
Sep-13-21 08:00AM	Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe (GlobeNewswire) -7.55%
Sep-09-21 08:00AM	Monopar Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire) +9.89%
Aug-12-21 08:00AM	Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates (GlobeNewswire)
Aug-05-21 08:00AM	Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial (GlobeNewswire)
Aug-03-21 08:00AM	Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma (GlobeNewswire)
Jul-12-21 08:00AM	Monopar Appoints Octávio Costa, MD, as Chief Medical Officer (GlobeNewswire)
Jun-24-21 08:00AM	Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO (GlobeNewswire) +7.99%
Jun-03-21 08:00AM	Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer (GlobeNewswire)
May-26-21 08:00AM	Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic (GlobeNewswire) +9.71%
May-24-21 08:00AM	Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery (GlobeNewswire)

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cittadine Andrew	Chief Operating Officer	Jun 20 '24	Buy	0.74	20,508	15,254	186,132	Jun 21 05:16 PM
Cittadine Andrew	Chief Operating Officer	Jun 18 '24	Buy	0.86	12,000	10,320	165,624	Jun 21 05:16 PM
Cittadine Andrew	Chief Operating Officer	Jun 14 '24	Buy	0.93	12,000	11,176	141,624	Jun 17 06:08 PM
Cittadine Andrew	Chief Operating Officer	Jun 13 '24	Buy	0.91	12,000	10,920	129,624	Jun 17 06:08 PM
Cittadine Andrew	Chief Operating Officer	Jun 17 '24	Buy	0.90	12,000	10,799	153,624	Jun 17 06:08 PM
Cittadine Andrew	Chief Operating Officer	Jun 04 '24	Buy	0.78	12,000	9,360	117,624	Jun 05 06:12 PM
Cittadine Andrew	Chief Operating Officer	Jun 03 '24	Buy	0.76	12,000	9,120	105,624	Jun 05 06:12 PM
Cittadine Andrew	Chief Operating Officer	May 31 '24	Buy	0.64	12,000	7,732	93,624	May 31 04:56 PM
Cittadine Andrew	Chief Operating Officer	May 30 '24	Buy	0.64	12,000	7,676	81,624	May 31 04:56 PM
Cittadine Andrew	Chief Operating Officer	May 29 '24	Buy	0.64	12,000	7,643	69,624	May 31 04:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MNPR

Monopar Therapeutics Inc

Upgrade your FINVIZ experience